Blake Paterson
Corporate Officer/Principal bei The American Board of Anesthesiology, Inc.
Profil
Blake M.
Paterson is the founder of Alba Therapeutics Corp.
(founded in 2004) and Avalo Therapeutics, Inc. (founded in 2011).
At Avalo Therapeutics, Inc., he held the title of President, Chief Executive Officer & Director from 2011 to 2015.
Currently, he is a Principal at The American Board of Anesthesiology, Inc. Dr. Paterson has previously worked as Director-Oncology Acute Care at Eli Lilly & Co., Director at Parke-Davis & Co. Ltd., and Chief Operating Officer at Integrity Pharmaceutical Corp.
He received his undergraduate degree from Tufts University and his doctorate from the University of Vermont.
Dr. Paterson is also the founder of Arbor Research & Trading LLC.
Aktive Positionen von Blake Paterson
Unternehmen | Position | Beginn |
---|---|---|
The American Board of Anesthesiology, Inc.
The American Board of Anesthesiology, Inc. Medical/Nursing ServicesHealth Services The American Board of Anesthesiology, Inc. is a voluntary association of lawyers that works to improve the administration of justice and promote programs that assist lawyers and judges in their work. The non-profit company is based in Raleigh, NC. The company also accredits law schools, provide continuing legal education, and work to build public understanding of the importance of the rule of law. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Blake Paterson
Unternehmen | Position | Ende |
---|---|---|
AVALO THERAPEUTICS, INC. | Gründer | 31.12.2015 |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Gründer | - |
Parke-Davis & Co. Ltd.
Parke-Davis & Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Parke-Davis & Co. Ltd. is a British pharmaceutical company. The company is based in St. Helier, UK. | Direktor/Vorstandsmitglied | - |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Integrity Pharmaceutical Corp. | Geschäftsführer | - |
Ausbildung von Blake Paterson
Tufts University | Undergraduate Degree |
University of Vermont | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
AVALO THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
The American Board of Anesthesiology, Inc.
The American Board of Anesthesiology, Inc. Medical/Nursing ServicesHealth Services The American Board of Anesthesiology, Inc. is a voluntary association of lawyers that works to improve the administration of justice and promote programs that assist lawyers and judges in their work. The non-profit company is based in Raleigh, NC. The company also accredits law schools, provide continuing legal education, and work to build public understanding of the importance of the rule of law. | Health Services |
Arbor Research & Trading LLC
Arbor Research & Trading LLC Investment ManagersFinance Founded in 1988, Arbor Research & Trading LLC is an institutional research and brokerage firm located in Barrington, Illinois. The firm produces innovative research across a broad range of global fixed-income, equity, currency and commodity markets. In addition, Arbor's trading desk provides comprehensive issue discovery and high quality execution in the fixed-income and currency markets. The firm offers objective viewpoints and intelligent solutions for portfolio managers and traders worldwide through a proprietary menu of independent and innovative research products designed to work in conjunction with clients and their systems. | Finance |
Integrity Pharmaceutical Corp. | Health Technology |
Parke-Davis & Co. Ltd.
Parke-Davis & Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Parke-Davis & Co. Ltd. is a British pharmaceutical company. The company is based in St. Helier, UK. | Health Technology |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Health Technology |